Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab.
作者信息
van der Schoot Lara S, Atalay Selma, Otero Marisol E, Kievit Wietske, van den Reek Juul M P A, de Jong Elke M G J
机构信息
Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands.
Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
出版信息
Br J Dermatol. 2022 Dec;187(6):1028-1030. doi: 10.1111/bjd.21797. Epub 2022 Aug 20.
Abstract
摘要
相似文献
1
Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab.在停用阿达木单抗、依那西普或乌司奴单抗剂量减少的银屑病患者中恢复充分的治疗反应。
Br J Dermatol. 2022 Dec;187(6):1028-1030. doi: 10.1111/bjd.21797. Epub 2022 Aug 20.
2
Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.儿童银屑病的生物治疗：一项回顾性观察研究，评估生物药物在儿童银屑病日常治疗中的生存情况。
J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1984-1992. doi: 10.1111/jdv.15579. Epub 2019 Apr 15.
3
Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice.在日常实践中，对银屑病患者进行生物制剂阿达木单抗、依那西普和乌司奴单抗的剂量减少策略试验的两年随访。
J Dermatolog Treat. 2022 May;33(3):1591-1597. doi: 10.1080/09546634.2020.1869147. Epub 2021 Jan 7.
4
Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial.在银屑病患者中通过延长阿达木单抗、依那西普和乌司奴单抗给药间隔进行剂量递减时的血清药物水平和抗药物抗体：CONDOR试验结果
J Dermatolog Treat. 2022 Aug;33(5):2680-2684. doi: 10.1080/09546634.2022.2043546. Epub 2022 Feb 23.
5
Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register study.中重度银屑病患者使用生物制剂治疗剂量递增的频率和结局：一项瑞典登记研究。
J Dermatolog Treat. 2024 Dec;35(1):2398170. doi: 10.1080/09546634.2024.2398170. Epub 2024 Sep 4.
6
Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice.实现银屑病患者阿达木单抗、依那西普和乌司奴单抗方案剂量降低的步骤。
J Dermatolog Treat. 2023 Dec;34(1):2186728. doi: 10.1080/09546634.2023.2186728.
7
Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.银屑病的生物疗法：从临床角度进行的依从性与疗效分析。
Australas J Dermatol. 2016 May;57(2):137-40. doi: 10.1111/ajd.12294. Epub 2015 Mar 5.
8
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.BADBIR 中符合临床试验条件和不符合临床试验条件的患者在停药、疗效和安全性方面的比较。
JAMA Dermatol. 2018 May 1;154(5):581-588. doi: 10.1001/jamadermatol.2018.0183.
9
Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.使用注射用生物制剂阿达木单抗、依那西普和乌司奴单抗治疗银屑病患者的特征分析：一项病历回顾研究。
J Dermatolog Treat. 2016 Aug;27(4):339-45. doi: 10.3109/09546634.2015.1118427. Epub 2015 Dec 17.
10
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.阿达木单抗、依那西普和乌司奴单抗治疗儿童和青少年斑块状银屑病：系统评价和经济评估。
Health Technol Assess. 2017 Nov;21(64):1-244. doi: 10.3310/hta21640.
引用本文的文献
1
Real-world individual and comparative analysis of adverse event reporting for adalimumab and etanercept using public FDA adverse event reporting system data.使用美国食品药品监督管理局公开的不良事件报告系统数据，对阿达木单抗和依那西普的不良事件报告进行真实世界的个体和对比分析。
Arch Dermatol Res. 2024 Dec 30;317(1):161. doi: 10.1007/s00403-024-03626-5.
2
Dose reduction of biologics in patients with plaque psoriasis: a review.斑块状银屑病患者生物制剂的剂量减少：一项综述
Front Pharmacol. 2024 Mar 28;15:1369805. doi: 10.3389/fphar.2024.1369805. eCollection 2024.
3
Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice.实现银屑病患者阿达木单抗、依那西普和乌司奴单抗方案剂量降低的步骤。
J Dermatolog Treat. 2023 Dec;34(1):2186728. doi: 10.1080/09546634.2023.2186728.
本文引用的文献
1
Biological Therapy Interruption and Re-Treatment in Chronic Plaque Psoriasis.生物制剂治疗中断与慢性斑块状银屑病的再治疗。
J Drugs Dermatol. 2021 Oct 1;20(10):1063-1071. doi: 10.36849/JDD.5716.
2
Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice.日常实践中阿达木单抗、依那西普和乌司奴单抗在银屑病患者中的一步式剂量减少策略评估
Acta Derm Venereol. 2021 May 25;101(5):adv00463. doi: 10.2340/00015555-3815.
3
Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review.银屑病患者生物制剂的剂量递减：范围综述。
Drugs. 2021 Feb;81(3):349-366. doi: 10.1007/s40265-020-01448-z.
4
Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study.与标准银屑病治疗相比，阿达木单抗、依那西普和乌司奴单抗严格控制剂量减少策略的健康经济后果：CONDOR研究的成本效用分析。
Acta Derm Venereol. 2020 Dec 1;100(19):adv00340. doi: 10.2340/00015555-3692.
5
Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial.与常规护理相比，对银屑病患者进行严格控制剂量减少生物制剂治疗的效果比较：一项随机临床试验。
JAMA Dermatol. 2020 Apr 1;156(4):393-400. doi: 10.1001/jamadermatol.2019.4897.
6
Adalimumab Dose Tapering in Psoriasis: Predictive Factors for Maintenance of Complete Clearance.阿达木单抗在银屑病中的剂量逐渐减少：维持完全清除的预测因素。
Acta Derm Venereol. 2017 Mar 10;97(3):346-350. doi: 10.2340/00015555-2571.
7
Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study.银屑病患者中阿达木单抗和依那西普的减量治疗：一项多中心观察性研究。
Acta Derm Venereol. 2016 Feb;96(2):251-2. doi: 10.2340/00015555-2209.
8
'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network.生物捕获网络：在日常实践护理中，阿达木单抗、依那西普和乌司奴单抗治疗银屑病的“快乐”药物存活率：结果。
Br J Dermatol. 2014 Nov;171(5):1189-96. doi: 10.1111/bjd.13087. Epub 2014 Oct 3.
Zotero 插件